Trade news

Challenges and detection of replication virus RCL/RCR in deep cell therapy

Public date:2024-10-11 09:17:36  Views:

Chimeric Antigen Receptor T Cell (CAR-T) therapy products have become a new hotspot in the field of international tumor immunotherapy research due to their significant therapeutic effects in hematological tumors, and have also become a new hope for curing tumors.

However, there is a potential risk of replication competent virus (RCV) contamination in the production of CAR-T cell products, and regulatory agencies require testing for RCV in clinical use of lentiviral or retroviral vectors, transduced CAR-T cell products, and patients.